Funding Details
- Awarder
- Inbox
- Date Award
- May 13, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Founding Year
- 2018
- Traction
- Azafaros is set to initiate Phase 3 studies for its lead product nizubaglustat for Niemann-Pick disease Type C and GM1/GM2 gangliosidoses later this year.
- Founders
- BGV
- Company Description
- Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
- Market
- Rare lysosomal storage disorders
- Location
-
Leiden,
Netherlands
- Coinvestors
- Jeito Capital, Forbion Growth, Seroba, Pictet Group, Forbion Ventures, Schroders Capital, BioGeneration Ventures
Links